VMViktoriya Konstantinovna Maltseva

Viktoriya Konstantinovna Maltseva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Viktoriya Konstantinovna Maltseva has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PHARMACEUTICAL DEVELOPMENT FOR PHLEBOPROTECTIVE AND ANTI-INFLAMMATORY GELS: ANALYTICAL SUPPORT OF THE TECHNOLOGICAL PROCESS

    by V.K. Maltseva, E.A. Samoshina, M.S. Makieva, E.F. Stepanova

    External soft dosage forms with a penetrating effect of different efficacy have proved promising in the treatment of inflammatory diseases. Moreover, there are few such medicines on the modern pharmaceutical market, and replenishment of their assortment is relevant. Objective. The purpose of these studies is to develop external soft dosage forms for various purposes using penetrators, their technological features and analysis. Material and methods. The work used: purified micronized flavonoid fraction (diosmin+flavonoids in terms of hesperidin), which has a phleboprotec-tive effect; Tizol – aquacomplex of titanium glycerosolvate is a metal complex compound with anti-inflammatory and antimicrobial action; L-arginine is an essential amino acid, a nitrogen donor; auxiliary substances: Polyethylene Oxide 400, Polyethylene Oxide 1500, Propylene Glycol-1,2. The studies were carried out using spectrophotometric determination, biopharmaceutical determination of a penetrator in a dental gel. Results. Optimal compositions of ointment and gel were developed, a general technological scheme of production was designed. Based on the analy-sis of the technological scheme, we recorded the critical stages of the process common to both objects. As for the methods for the quantitative anal-ysis of ointment with a flavonoid complex, they are validated. Studies on the microbiological purity of dental gel allowed us to make an unambiguous conclusion about the sterility of the gel. This, in turn, ensures the effectiveness of therapy with such a drug, due to the absence of side microbiological contamination during use, as well as the absence of the risk of concomitant diseases. Conclusion. As a result of the conducted research, compositions of external soft dosage forms of phleboprotective and dental profile containing pene-trating components were developed.


  • The choice of excipients in the development of a soft dosage form of phleboprotective action containing a micronized flavonoid fraction

    by Viktoriya Konstantinovna Maltseva, Eleonora Fedorovna Stepanova, Evgeniya Olegovna Kulichenko, Marina Sergeevna Makieva

    Varicose veins are called one of the diseases of the 21st century, caused by a sedentary lifestyle and genetics. The purpose of this study was the development of ointment compositions containing the micronized flavonoid fraction and the study of the degree of release of the micronized fraction by the flavonoid from the ointment compositions with penetrating components. With the obtained ointment compositions, a complex of biopharmaceutical studies in vitro was carried out: release from ointment compositions by diffusion into a gelatin gel and dialysis through a semipermeable membrane, while the quality indicators of the ointment compositions were established. The conducted in vitro biopharmaceutical studies helped to determine the final composition of the ointment in relation to the auxiliary composition: active ingredient — 2%, PEG 1500:PEG 400 (7:3), propylene glycol — 1%.

  • Open Access

    PHLEBOPROTECTORS BASED ON FLAVONOIDS: DOSAGE FORMS, BIOPHARMACEUTICAL CHARACTERISTICS, TECHNOLOGICAL FEATURES

    by E. F. Stepanova, I. P. Remezova, A. M. Shevchenko, A. V. Morozov, V. K. Maltseva

    Micronized purified flavonoid fraction (MPFF) is the original phlebotropic drug. Its marketed form (Detralex®) consists of 90% diosmin and 10% of other flavonoids. Calculated as hesperidin, it is the most widely used drug today. Diosmin and hesperidin, which are parts of the majority of venoactive drugs, are sparingly water-soluble compounds, and this feature can effect on their clinical efficacy. One of the ways to increase the solubility of these compounds leading to an increase in bioavailability, is the micronization of the active ingredients.The aim of the investigation is a comparative determination of the dynamics and dissolution efficiency of the drugs containing bioflavonoid fractions in the dissolution test, as well as the analysis of the micronization degree and its impact on technology and biopharmaceutical parameters.Materials and methods. A biopharmaceutical release profile was determined using HPLC. Disintegration, characteristics of the shape and size of the tablets’ particles were determined according to the methods of the State Pharmacopoeia of the XIV-th edition.Results. The objects created with the use of diosmin and hesperidin, have been considered in detail. The role of technological solutions in relation to the corresponding dosage forms is notified. Detailed biopharmaceutical characteristics have been established with a choice of HPLC-based release control methodology. All the drugs in this group have a low water solubility leading to the maximum bioavailability for Detralex® which is about 1.26%; and no more than 0.2% for other analyzed models.Conclusion. Detralex® dominates among the analyzed objects (tablets) in terms of the release rate. With regard to the overall quantitative indicators of release, the actual numbers are quite low, which is associated with the poor water solubility of the active substances.